A company already makes a finished antibiotic in India, at scale, on an active ingredient it imports. Over a few years, the government offers three kinds of manufacturing incentive. First, a payment for every kilogram of that input made at home. Then cheap land and shared utilities to build the plant inside a dedicated park. Most recently, research grants and patient capital to develop the fermentation process itself and carry it to scale. Three incentives, three different things paid for. What is the state trying to buy, and why does it keep changing what it puts on the table?
The familiar reading is that India is the pharmacy of the world and merely needs to extend that strength upstream into its own raw materials. The incentives tell a more honest story about what was there to begin with. For the class of fermentation-based antibiotics at the centre of this anxiety, the country did once make the key starting material; in the 1990s a handful of firms and a public sector unit produced it. That capability was thin and sub-scale, and it did not lapse through any loss of technical knowledge. It lapsed through a sequence the state itself set in motion: the input was taken off the import-restriction list early in the 2000s, cheaper imported material undercut the domestic price by roughly half, and the price ceiling on finished medicines pushed every formulator toward the lowest-cost input. The domestic producers withdrew one after another over the following decade. What China built in those same years was not a larger copy of what India had; it was an industrial ecosystem of a scale and cost India had never possessed. What had to be closed was therefore never a single molecule. It was the chemistry, the utilities, the effluent capacity, and the process refinement that sit underneath the molecule.
This is why the incentive keeps changing, and why the change is the real signal. The Production Linked Incentive paid for output: a sum on each unit of the input produced domestically, designed to make a once-viable molecule viable again. It restarted a few plants, but it could not alter the cost structure that had killed them, because a payment per kilogram does not build a cluster or refine a process. The Bulk Drug Parks funded shared infrastructure: common utilities and effluent treatment in dedicated locations, an attempt to manufacture the cost advantage that scale and clustering give a competitor. The most recent layer funds something neither of the first two could reach, and it arrives in two coordinated forms. A subsidy on output assumes the capability already exists and only needs to be made profitable; capital deployed this far upstream assumes the capability has to be built before profit is even a question. Through the Anusandhan National Research Foundation, grant money flows into the science base itself, into the national laboratories and the government's own pharmaceutical research institutes, the National Institute of Pharmaceutical Education and Research, the NIPER network, where the process chemistry that was never built at scale is developed. Alongside it, the Research, Development and Innovation Fund carries that science toward industrial scale through patient capital, equity, convertible instruments and long-term debt, deployed through dedicated managers such as the Biotechnology Industry Research Assistance Council and directed at the inputs where dependence on a single source runs highest. Over all of it sits the biomanufacturing policy, BioE3, Biotechnology for Economy, Environment and Employment, which places high-value chemicals, active ingredients and enzymes at the front of its priorities and treats fermentation capacity as a strategic asset to be created rather than a market to be subsidised.
For a practitioner, the lesson sits in the migration itself. The state has worked out that ownership of a stack cannot be purchased by the kilogram; it has to be capitalised like an industry that does not yet exist. Reading any one of these incentives alone, a company sees a scheme to be qualified for. Reading them in sequence, it sees the government revising its own theory of the problem in real time: from the belief that the chemistry merely needed to be made profitable again, to the recognition that it has to be financed into being from the science upward. The country is not trying to assemble the world's medicines a little more cheaply than before. It is trying to own the biology and the chemistry beneath them, and each new incentive is an admission that the previous one was aimed one layer too shallow.